Oncology Preclinical Deal Benchmarks (2026)

Understanding Oncology Deal Benchmarks at Preclinical

Preclinical Oncology licensing deals command a median upfront payment of $64M, with values ranging from $21M at the low end to $110M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the oncology therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $397M to $1.6B, with a median of $993M. Royalty rates for oncology assets at this stage typically fall between 5.1% and 11.1% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.